RANI THERAPEUTICS HOLDINGS-A (RANI) Fundamental Analysis & Valuation

NASDAQ:RANI • US7530181004

Current stock price

0.7681 USD
+0.03 (+4.53%)
Last:

This RANI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RANI Profitability Analysis

1.1 Basic Checks

  • RANI had negative earnings in the past year.
  • In the past year RANI has reported a negative cash flow from operations.
  • RANI had negative earnings in each of the past 5 years.
  • RANI had a negative operating cash flow in each of the past 5 years.
RANI Yearly Net Income VS EBIT VS OCF VS FCFRANI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • RANI's Return On Assets of -50.62% is on the low side compared to the rest of the industry. RANI is outperformed by 63.02% of its industry peers.
  • RANI has a worse Return On Equity (-89.89%) than 62.50% of its industry peers.
Industry RankSector Rank
ROA -50.62%
ROE -89.89%
ROIC N/A
ROA(3y)-63.74%
ROA(5y)-45.25%
ROE(3y)-620.28%
ROE(5y)-392.26%
ROIC(3y)N/A
ROIC(5y)N/A
RANI Yearly ROA, ROE, ROICRANI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

1.3 Margins

  • RANI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RANI Yearly Profit, Operating, Gross MarginsRANI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RANI Health Analysis

2.1 Basic Checks

  • RANI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RANI has more shares outstanding
  • Compared to 5 years ago, RANI has more shares outstanding
  • RANI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RANI Yearly Shares OutstandingRANI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
RANI Yearly Total Debt VS Total AssetsRANI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • RANI has an Altman-Z score of -2.37. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of RANI (-2.37) is comparable to the rest of the industry.
  • RANI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.37
ROIC/WACCN/A
WACC10.33%
RANI Yearly LT Debt VS Equity VS FCFRANI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • RANI has a Current Ratio of 4.21. This indicates that RANI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of RANI (4.21) is better than 60.94% of its industry peers.
  • RANI has a Quick Ratio of 4.21. This indicates that RANI is financially healthy and has no problem in meeting its short term obligations.
  • RANI's Quick ratio of 4.21 is fine compared to the rest of the industry. RANI outperforms 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 4.21
RANI Yearly Current Assets VS Current LiabilitesRANI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RANI Growth Analysis

3.1 Past

  • RANI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.34%, which is quite impressive.
  • Looking at the last year, RANI shows a very strong growth in Revenue. The Revenue has grown by 58.85%.
  • RANI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.84% yearly.
EPS 1Y (TTM)44.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
Revenue 1Y (TTM)58.85%
Revenue growth 3YN/A
Revenue growth 5Y28.84%
Sales Q2Q%42.02%

3.2 Future

  • Based on estimates for the next years, RANI will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.94% on average per year.
  • The Revenue is expected to grow by 99.71% on average over the next years. This is a very strong growth
EPS Next Y53.32%
EPS Next 2Y22.95%
EPS Next 3Y5.89%
EPS Next 5Y11.94%
Revenue Next Year30.15%
Revenue Next 2Y50.6%
Revenue Next 3Y87.08%
Revenue Next 5Y99.71%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RANI Yearly Revenue VS EstimatesRANI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
RANI Yearly EPS VS EstimatesRANI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. RANI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.
  • Also next year RANI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RANI Price Earnings VS Forward Price EarningsRANI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RANI Per share dataRANI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.95%
EPS Next 3Y5.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RANI Dividend Analysis

5.1 Amount

  • RANI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RANI Fundamentals: All Metrics, Ratios and Statistics

RANI THERAPEUTICS HOLDINGS-A

NASDAQ:RANI (4/1/2026, 12:48:07 PM)

0.7681

+0.03 (+4.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26
Earnings (Next)N/A
Inst Owners47.89%
Inst Owner Change850.26%
Ins Owners3.07%
Ins Owner Change58.52%
Market Cap93.34M
Revenue(TTM)1.63M
Net Income(TTM)-29.67M
Analysts82.22
Price Target8.16 (962.36%)
Short Float %11.49%
Short Ratio9.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.84%
Min EPS beat(2)-2.94%
Max EPS beat(2)4.61%
EPS beat(4)2
Avg EPS beat(4)1.27%
Min EPS beat(4)-6.08%
Max EPS beat(4)9.5%
EPS beat(8)4
Avg EPS beat(8)-1.33%
EPS beat(12)8
Avg EPS beat(12)3.32%
EPS beat(16)12
Avg EPS beat(16)11.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.51%
PT rev (3m)-13.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)7.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57.16
P/FCF N/A
P/OCF N/A
P/B 2.83
P/tB 2.83
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.01
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.62%
ROE -89.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.74%
ROA(5y)-45.25%
ROE(3y)-620.28%
ROE(5y)-392.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.78%
Cap/Sales 5.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.21
Quick Ratio 4.21
Altman-Z -2.37
F-Score5
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)61.79%
Cap/Depr(5y)116.38%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
EPS Next Y53.32%
EPS Next 2Y22.95%
EPS Next 3Y5.89%
EPS Next 5Y11.94%
Revenue 1Y (TTM)58.85%
Revenue growth 3YN/A
Revenue growth 5Y28.84%
Sales Q2Q%42.02%
Revenue Next Year30.15%
Revenue Next 2Y50.6%
Revenue Next 3Y87.08%
Revenue Next 5Y99.71%
EBIT growth 1Y22.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-62.4%
EBIT Next 3Y1.96%
EBIT Next 5Y38.73%
FCF growth 1Y47.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.28%
OCF growth 3YN/A
OCF growth 5YN/A

RANI THERAPEUTICS HOLDINGS-A / RANI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RANI THERAPEUTICS HOLDINGS-A?

ChartMill assigns a fundamental rating of 4 / 10 to RANI.


What is the valuation status of RANI THERAPEUTICS HOLDINGS-A (RANI) stock?

ChartMill assigns a valuation rating of 0 / 10 to RANI THERAPEUTICS HOLDINGS-A (RANI). This can be considered as Overvalued.


How profitable is RANI THERAPEUTICS HOLDINGS-A (RANI) stock?

RANI THERAPEUTICS HOLDINGS-A (RANI) has a profitability rating of 0 / 10.


Can you provide the financial health for RANI stock?

The financial health rating of RANI THERAPEUTICS HOLDINGS-A (RANI) is 7 / 10.


What is the expected EPS growth for RANI THERAPEUTICS HOLDINGS-A (RANI) stock?

The Earnings per Share (EPS) of RANI THERAPEUTICS HOLDINGS-A (RANI) is expected to grow by 53.32% in the next year.